Alectinib approved for the treatment of ALK-positive NSCLC

A new treatment that targets a specific type of lung cancer has received FDA approval. Alectinib has been approved in the US for the treatment of patients with ALK (anaplastic lymphoma kinase)-positive non-small cell lung cancer (NSCLC) whose disease had worsened after – or who could not tolerate –  treatment with crizotinib [1].

 

Alectinib for ALK-positive NSCLC.

An ALK (anaplastic lymphoma kinase) is a gene mutation that can occur in various cancer cells, including lung cancer cells. ALK gene mutations are present in about 5 % of patients with NSCLC.

Alectinib is an oral medication that blocks the activity of the ALK protein, which may prevent NSCLC cells from growing and spreading [1]. Its approval provides a new therapy for patients who would have had few treatment options if their disease stopped responding to treatment with crizotinib. Furthermore, clinical trials provide evidence of an effect on tumours that had spread to the brain [1], which is common in ALK-positive NSCLC metastatic patients [2].

If you live outside the US you can order alectinib at thesocialmedwork.com when a doctor’s prescription is provided.

More information about the safety and efficacy of alectinib can be found at the following links:

DISCLAIMER: Nothing can replace the care of your clinician or doctor. Please do not make changes to your treatment or schedules without first consulting your healthcare providers. This article is not intended to diagnose or treat illness.

© TheSocialMedwork





Comments

1495


Comment


Registered with the Dutch Ministry of Health as an independent intermediary, Registration number 6730 BEM



Share our website

Follow us


DISCLAIMER: The Services of TheSocialMedwork do not replace a physician-patient relationship and are not intended as medical advice. TheSocialMedwork provides patients and physicians with existing treatment options abroad and creates access to these options after the patient and physician have made a professional decision. Privacy Policy / Terms and Conditions
Our service uses cookies.